NCT03141827View on ClinicalTrials.gov

The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

February 15, 2017

Study Completion Date

April 26, 2017

Conditions
Hyperlipidemia
Interventions
DRUG

Insulin

Insulin 40 IU, nasal spray, single dose

DRUG

Placebo

Placebo, nasal spray, single dose

Trial Locations (1)

M5G 1L7

Tornto General Hospital, UHN, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03141827 - The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production | Biotech Hunter | Biotech Hunter